China-based gene therapy specialist Neurophth Biotechnology Ltd has reportedly secured close to RMB700 million in a Series C+ financing round. The round was led by Changjiang Zhaoyin Industrial Fund, Optics Valley Financial Holing, Wuhan Hi-Tech, and Optics Valley Industrial Investment, all state-owned entities, along with Guangzhou Finance Holdings. This financing includes contributions from SDIC Investment, Silicon Paradise Equity Investment, and Yangtze Investment. The funds will be utilized to accelerate clinical trials, enhance R&D capabilities, and expand the company’s product pipeline.
NR082: A Milestone in Gene Therapy
Neurophth’s flagship product, NR082 (rAAV2-ND4, NFS-01), a recombinant adeno-associated virus serotype 2 (rAAV2), has become the first of its kind to complete Phase III study enrollment in China this year. Additionally, it has finalized the first patient enrollment of a Phase I/II study in the US. This achievement marks a significant step forward in the development of gene therapy treatments for retinal diseases.
NFS-02: A Global First in ND1-LHON Gene Therapy
The company’s second gene therapy, NFS-02 (rAAV2-ND1), which targets ND1 mutation-induced Leber hereditary optic neuropathy (ND1-LHON), is currently the world’s only gene therapy for this condition. It has received tacit approval for clinical trials in both China and the US, highlighting Neurophth’s leading position in the gene therapy space.-Fineline Info & Tech
